Tenax Therapeutics (NASDAQ:TENX) has completed Phase 3 enrollment for oral levosimendan (TNX‑103) in PH‑HFpEF and is prepping a database lock and analysis ahead of expected August 2026 topline results, while issuing 160,000 inducement options to three non‑executive hires.
Previous Week Recap
- Phase 3 LEVEL Enrollment Completed: Tenax (TENX) completed Phase 3 LEVEL enrollment for oral levosimendan (TNX-103) in PH-HFpEF. Topline results expected August 2026; company preparing database lock and analysis.
- Inducement Options Granted: Tenax Therapeutics (TENX) granted 160,000 inducement options to three non‑executive hires on July 1, 2026. Options at Nasdaq close price; 25% vest after 1 year, remainder monthly over 36 months.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.